Innovent Announces NMPA Acceptance of New Drug Application for the FGFR1/2/3 Inhibitor (Pemigatinib) for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or ...Middle East

SAN FRANCISCO, and SUZHOU, China, July 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other...

Hence then, the article about innovent announces nmpa acceptance of new drug application for the fgfr1 2 3 inhibitor pemigatinib for the treatment of adults with previously treated unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or was published today ( Friday 09/07/2021 - 03:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces NMPA Acceptance of New Drug Application for the FGFR1/2/3 Inhibitor (Pemigatinib) for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or )

Also on site :

• Ukraine-Russia war latest: Xi reportedly told Trump that Putin might ‘regret’ invading Ukraine
• With Just Two Looks, Taylor Russell Is Already In the Running for Best-Dressed at Cannes
• Un estudio señala que las demoras en Lima durante las elecciones no habrían afectado el resultado en Perú